Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07150793 · ClinicalTrials.gov registry record
A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 754
- Enrollment target
NCT07150793 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 754 participants.
The verdict
NCT07150793 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 754 participants
- Enrollment target
Study Summary
The main goal of this study was to describe treatment patterns of patients with chronic myeloid leukemia (CML) who were treated with tyrosine kinase inhibitors (TKIs) in Japan. This was a retrospective observational study with secondary use of data from the Medical Data Vision (MDV) hospital-based database. The index date was the date of the first prescription of any TKI of interest registered within the selection period (01 January 2011 to 31 December 2019). The follow-up period was from the index date until the end of the study period, end of continuous follow-up in the MDV database, or death, whichever came first.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 754 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2023-02-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07150793
The ClinicalTrials.gov registry entry for NCT07150793 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 754 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07150793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07150793 about?
NCT07150793 is a clinical study titled "A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan". The main goal of this study was to describe treatment patterns of patients with chronic myeloid leukemia (CML) who were treated with tyrosine kinase inhibitors (TKIs) in Japan. This was a retrospective observational study with secondary use of data from the Medical Data Vision (MDV) hospital-based ...
What is the current status of trial NCT07150793?
This trial is currently completed. The enrollment target is 754 participants. The study started on 2022-07-05. Estimated completion is 2023-02-08.
Who is sponsoring clinical trial NCT07150793?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.